



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**AMEX: RNN**

Last Trade:	2.41
Trade Time:	8:00 PM ET 01/22/18
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.67 - 7.10
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 01/22/18**  
[Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers \(ASCO GI\) 2018 Annual Meeting](#)
- 01/18/18**  
[Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers \(ASCO GI\) 2018 Annual Meeting](#)
- 01/08/18**  
[Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018](#)
- 01/04/18**  
[Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer](#)
- 12/11/17**  
[Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- 02/24/17**  
[Annual Report \(10-K\)](#)
- 02/24/17**  
[Proxy Statement \(DEF 14A\)](#)
- 11/03/17**  
[Quarterly Report \(10-Q\)](#)
- 08/04/17**  
[Quarterly Report \(10-Q\)](#)
- 05/03/17**  
[Quarterly Report \(10-Q\)](#)